BioAge Labs Inc (BIOA) concluded trading on Wednesday at a closing price of $4.30, with 4.7 million shares of worth about $20.21 million changed hands on the day. On December 18, 2024 the price saw a gain of about 4.88%. Currently the company’s common shares owned by public are about 34.20M shares, out of which, 20.46M shares are available for trading.
Stock saw a price change of -10.42% in past 5 days and over the past one month there was a price change of -76.27%. Over the period of past 52 weeks, stock dropped to lowest price of $3.85 but also hit the highest price of $26.62 during that period. The average intraday trading volume for BioAge Labs Inc shares is 669.34K. The stock is currently trading -66.85% below its 20-day simple moving average (SMA20), while that difference is down -76.89% for SMA50 and it goes to -77.30% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BioAge Labs Inc (NASDAQ: BIOA) currently have 34.20M outstanding shares and institutions hold larger chunk of about 32.39% of that.
The stock has a current market capitalization of $154.16M. It has Quick Ratio of 17.63 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BIOA, volatility over the week remained 13.90% while standing at 9.74% over the month.
Analysts are in expectations that BioAge Labs Inc (BIOA) stock would likely to be making an EPS of -0.66 in the current quarter, while forecast for next quarter EPS is -0.68 and it is -2.44 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.75 which is -0.5 at the higher side of the target for the same.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on December 10, 2024 offering an Underweight rating for the stock and assigned a target price range of between $40 and $5 to it. Coverage by Jefferies stated BioAge Labs Inc (BIOA) stock as a Hold in their note to investors on December 09, 2024, suggesting a price target of $7 for the stock. On December 09, 2024, Citigroup Downgrade their recommendations, while on October 21, 2024, Morgan Stanley Initiated their ratings for the stock with a price target of $40. Stock get a Buy rating from Jefferies on October 21, 2024.
